Grifols, S.A.
Ticker
GRFS
ISIN
ES017199608
Price
USD 8.60
Change Today
+0.14 / 1.655 %
Price 1 year ago
9.46 / -9.091 %
Market Capitalization
7,664,588,288.00
52 Week Low
5.47
52 Week High
11.56
200 Day Moving Average
7.75
50-day Moving Average
8.87
Price evolution
Yearly Returns
Peers
Peers
Company information
Summary
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Sector
Healthcare
Industry
Drug Manufacturers—General
Country
Spain
Exchange
NMS
Earnings Per Share
0.5425
P/E Ratio
14.672811
Debt/Equity Ratio
113.503
Beta
0.212745
Ebitda
698,905,024.00
Ebitda Margins
0.13
Enterprise to Ebitda
33.13
Enterprise Value
23,154,198,528.00
Target Price
16.06
Estimated Price
-
Book Value
3.73
Expected Growth
-
Balance sheet
Income statement
Sustainability
Correlation
| Company | Name | Correlation |
|---|---|---|
| KLBF.JK | Kalbe Farma Tbk. | -0.27 |
| 4568.T | DAIICHI SANKYO COMPANY LIMITED | -0.12 |
| 600276.SS | JIANGSU HENGRUI MEDICAL CO LTD | -0.09 |
| 600572.SS | ZHEJIANG CONBA PHARMACEUTICAL C | -0.06 |
| LLY | Eli Lilly and Company | -0.00 |
| PFE | Pfizer, Inc. | -0.00 |
| 600713.SS | NANJING PHARMACEUTICAL CO LTD | 0.01 |
| 600436.SS | ZHANGZHOU PIENTZEHUANG PHARMACE | 0.08 |
| GSK.L | GSK PLC | 0.10 |
| 600771.SS | GUANGYUYUAN CHINESE HERBAL MEDI | 0.10 |
| 300006.SZ | CHONGQING LUMMY PH | 0.11 |
| JNJ | Johnson & Johnson | 0.11 |
| 600867.SS | TONGHUA DONGBAO MEDICINES CO LT | 0.12 |
| GILD | Gilead Sciences, Inc. | 0.12 |
| ABBV | AbbVie Inc. | 0.12 |
| BMY | Bristol-Myers Squibb Company | 0.12 |
| ECILC.IS | ECZACIBASI ILAC | 0.13 |
| MYX.AX | M PHARMA FPO | 0.22 |
| MRK | Merck & Company, Inc. | 0.25 |
| 1093.HK | CSPC PHARMA | 0.26 |
| NOVN.SW | NOVARTIS N | 0.27 |
| 4519.T | CHUGAI PHARMACEUTICAL CO | 0.27 |
| GSK | GSK plc | 0.27 |
| 4503.T | ASTELLAS PHARMA | 0.31 |
| AMGN | Amgen Inc. | 0.36 |
| 600613.SS | SHANGHAI SHENQI PHARM INVEST MA | 0.38 |
| HZNP | Horizon Therapeutics Public Lim | 0.42 |
| AZN | Astrazeneca PLC | 0.47 |
| 2186.HK | LUYE PHARMA | 0.48 |
Similar companies
| Ticker | Name | City | Country | Currency | Exchange | Beta | EV/EBITDA | Employees | Site |
|---|---|---|---|---|---|---|---|---|---|
| 600276.SS | JIANGSU HENGRUI MEDICAL CO LTD | Lianyungang | China | CNY | SHH | 58.73 | 24491 | https://www.hrs.com.cn | |
| KLBF.JK | Kalbe Farma Tbk. | Jakarta | Indonesia | IDR | JKT | 0.50 | 14.50 | 12392 | https://www.kalbe.co.id |
| 1093.HK | CSPC PHARMA | Shijiazhuang | China | HKD | HKG | 0.67 | 12.86 | 24746 | https://www.cspc.com.hk |
| 300006.SZ | CHONGQING LUMMY PH | Chongqing | China | CNY | SHZ | 0.83 | -32.33 | 935 | https://www.cqlummy.com |
| PFE | Pfizer, Inc. | New York | United States | USD | NYQ | 0.68 | 6.88 | 79000 | https://www.pfizer.com |
| 600572.SS | ZHEJIANG CONBA PHARMACEUTICAL C | Hangzhou | China | CNY | SHH | 0.46 | 10.69 | 8589 | https://www.conbagroup.com |
| 600713.SS | NANJING PHARMACEUTICAL CO LTD | Nanjing | China | CNY | SHH | 0.46 | 9.37 | 5062 | https://www.njyy.com |
| 600867.SS | TONGHUA DONGBAO MEDICINES CO LT | Tonghua | China | CNY | SHH | 0.24 | 12.42 | https://www.thdb.com | |
| ECILC.IS | ECZACIBASI ILAC | Istanbul | Turkey | TRY | IST | 0.20 | 71.70 | 336 | https://www.eczacibasi.com.tr/en/eczacibasi-gruop/companies/other-products-and-services |
| GSK.L | GSK PLC | Brentford | United Kingdom | GBp | LSE | 0.32 | 6.22 | 90096 | https://www.gsk.com |
| MRK | Merck & Company, Inc. | Kenilworth | United States | USD | NYQ | 0.36 | 10.37 | 67000 | https://www.merck.com |
| BMY | Bristol-Myers Squibb Company | New York | United States | USD | NYQ | 0.44 | 8.87 | 32200 | https://www.bms.com |
| 600771.SS | GUANGYUYUAN CHINESE HERBAL MEDI | Xi'an | China | CNY | SHH | 0.55 | -48.11 | 1900 | https://www.guangyuyuan.com |
| GILD | Gilead Sciences, Inc. | Foster City | United States | USD | NMS | 0.39 | 7.19 | 14400 | https://www.gilead.com |
| JNJ | Johnson & Johnson | New Brunswick | United States | USD | NYQ | 0.57 | 14.45 | 141700 | https://www.jnj.com |
| GSK | GSK plc | Brentford | United Kingdom | USD | NYQ | 0.18 | 8.08 | 90096 | https://www.gsk.com |
| AZN | Astrazeneca PLC | Cambridge | United Kingdom | USD | NMS | 0.12 | 18.55 | 83100 | https://www.astrazeneca.com |
| ABBV | AbbVie Inc. | North Chicago | United States | USD | NYQ | 0.75 | 11.46 | 50000 | https://www.abbvie.com |
| 2186.HK | LUYE PHARMA | Yantai | China | HKD | HKG | 0.75 | 14.06 | 4845 | https://www.luye.cn |
| 600613.SS | SHANGHAI SHENQI PHARM INVEST MA | Shanghai | China | CNY | SHH | 0.36 | 22.96 | 1371 | https://www.gzsq.com |
| MYX.AX | M PHARMA FPO | Salisbury South | Australia | AUD | ASX | 1.09 | 27.98 | https://www.maynepharma.com | |
| 4568.T | DAIICHI SANKYO COMPANY LIMITED | Tokyo | Japan | JPY | JPX | 52.12 | 16458 | https://www.daiichisankyo.com | |
| 4503.T | ASTELLAS PHARMA | Tokyo | Japan | JPY | JPX | 0.58 | 12.39 | 14522 | https://www.astellas.com |
| NOVN.SW | NOVARTIS N | Basel | Switzerland | CHF | EBS | 0.50 | 10.30 | 108000 | https://www.novartis.com |
| SNY | Sanofi | Paris | France | USD | NMS | 0.36 | 9.75 | 95442 | https://www.sanofi.com |
| HZNP | Horizon Therapeutics Public Lim | Dublin | Ireland | USD | NMS | 1.16 | 20.67 | 1940 | https://www.horizontherapeutics.com |
| LLY | Eli Lilly and Company | Indianapolis | United States | USD | NYQ | 0.37 | 29.00 | 35000 | https://www.lilly.com |
| AMGN | Amgen Inc. | Thousand Oaks | United States | USD | NMS | 0.58 | 12.61 | 24200 | https://www.amgen.com |
| 4519.T | CHUGAI PHARMACEUTICAL CO | Tokyo | Japan | JPY | JPX | 0.64 | 9.60 | 7664 | https://www.chugai-pharm.co.jp |
| 600436.SS | ZHANGZHOU PIENTZEHUANG PHARMACE | Zhangzhou | China | CNY | SHH | 0.78 | 57.53 | 2591 | https://www.zzpzh.com.cn |
| BAYN.DE | BAYER AG | Leverkusen | Germany | EUR | GER | 1.16 | 13.66 | 101914 | https://www.bayer.com |
| AZN.L | ASTRAZENECA PLC ORD SHS $0.25 | Cambridge | United Kingdom | GBp | LSE | 0.10 | 15.96 | 83100 | https://www.astrazeneca.com |
| 300357.SZ | ZHEJIANG WOLWO BIO | Huzhou | China | CNY | SHZ | 0.40 | 56.57 | 1488 | https://www.wolwobiotech.com |
| SAN.PA | SANOFI | Paris | France | EUR | PAR | 0.36 | 9.86 | 95442 | https://www.sanofi.com |
| NVS | Novartis AG | Basel | Switzerland | USD | NYQ | 0.49 | 10.62 | 108000 | https://www.novartis.com |
| 0P6S.IL | BAYER AG | Leverkusen | Germany | EUR | IOB | 1.15 | 9.51 | 100753 | https://www.bayer.com |
| CIPLA.NS | CIPLA LTD | Mumbai | India | INR | NSI | 17.91 | https://www.cipla.com | ||
| 4528.T | ONO PHARMACEUTICAL CO | Osaka | Japan | JPY | JPX | 0.33 | 13.40 | 3687 | https://www.ono-pharma.com |
| 4536.T | SANTEN PHARMACEUTICAL CO | Osaka | Japan | JPY | JPX | 0.37 | 7.05 | 4315 | https://www.santen.com |
| OGN | Organon & Co. | Jersey City | United States | USD | NYQ | 7.83 | 9300 | https://www.organon.com |
Funds
Mutual Fund Holders
Social
Dividends
Ratings
News
Earnings
SEC Filings
Options
Indicators
Glossary
- Momentum
- A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
- Inertia
- In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
- Relative Strength Index (RSI)
- A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
- Fibonacci's Weighted Moving Average
- A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
- Williams %R
- A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
- Relative Volatility Index (RVI)
- A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
- Commodity Channel Index (CCI)
- A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.